强肝胶囊对非酒精性脂肪肝肥胖患者糖脂代谢水平及肝功能的影响OACSTPCD
Effect of Qianggan Capsule on Glucose and Lipid Metabolism and Liver Function of Non-alcoholic Fatty Liver Obese Patients
目的:观察强肝胶囊对非酒精性脂肪肝患者糖脂代谢水平及肝功能的影响.方法:100 例非酒精性脂肪肝肥胖患者按照随机数字表法平均分为对照组和观察组.对照组给予二甲双胍治疗,观察组给予二甲双胍联合强肝胶囊.治疗12 周后,比较两组患者治疗前后糖脂代谢水平[低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)、三酰甘油(triacylglycer-ol,TG)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)、总胆固醇(total cholesterol,TC)、空腹血糖(fasting blood glucose,FBG)],肝功能指标[谷氨酰转移酶(gamma-glutamyltransferase,GGT)、丙氨酸转氨酶(alanine aminotransferase,ALT)、碱性磷酸酶(alkaline phosphatase,ALP)、天冬氨酸转氨酶(aspartate aminotransferase,AST)],并比较两组患者不良反应情况.结果:(1)治疗后,两组患者ALT、AST、GGT水平均明显下降(P<0.01);观察组治疗后ALP为(75.05±17.51)U·L-1,显著低于本组治疗前(83.71±20.41)U·L-1(P<0.05).(2)治疗后,观察组ALT为(32.54±9.02)U·L-1、GGT为(21.75±7.58)U·L-1,均显著低于同期对照组(P<0.01).(3)治疗后,对照组TG为(2.20±0.81)mmol·L-1、HDL-C(1.24±0.27)mmol·L-1,与治疗前比较,差异均有统计学意义(P<0.01、P<0.05);观察组TC为(4.34±0.81)mmol·L-1、TG为(1.74±0.76)mmol·L-1,显著低于治疗前(P<0.01).(4)治疗后,观察组TG为(1.74±0.76)mmol·L-1,显著低于同期对照组(2.20±0.81)mmol·L-1,差异有统计学意义(P<0.01).(5)治疗后两组FBG水平与治疗前比较,差异均有统计学意义(P<0.05).(6)两组患者治疗后脂肪肝程度经秩和检验,差异有统计学意义(Z =-2.685,P<0.01).结论:强肝胶囊能够改善非酒精性脂肪肝肥胖患者糖脂代谢水平,保护肝功能,减轻肝脏内脂肪含量.
Objective:To observe the effect of Qianggan Capsule on glucose and lipid metabolism levels and liver function in non-alco-holic fatty liver patients.Method:100 patients with non-alcoholic fatty liver obesity were evenly divided into a control group and an ob-servation group using a random number table method.The control group was treated with metformin,while the observation group was treated with metformin combined with Qianggan capsules.After 12 weeks of treatment,compare the glucose and lipid metabolism levels of two groups of patients before and after treatment[low-density lipoprotein cholesterol(LDL-C),triacylglycerol(TG),high-den-sity lipoprotein cholesterol(HDL-C),total cholesterol(TC),and fasting blood glucose(FBG)],Liver function indicators[gamma glutamyltransferase(GGT),alanine aminotransferase(ALT),alkaline phosphatase(ALP),aspartate aminotransferase(AST)],and the adverse reactions of the two groups of patients were compared.Results:(1)After treatment,the levels of ALT,AST,and GGT in both groups of patients significantly decreased(P<0.01);After treatment,the ALP of the observation group was(75.05±17.51)U·L-1 was significantly lower than the(83.71±20.41)U·L-1 before treatment in this group(P<0.05).(2)After treatment,the ALT and GGT of the observation group were(32.54±9.02)U·L-1 and(21.75±7.58)U·L-1,both significantly lower than those of the control group during the same period(P<0.01).(3)After treatment,the TG of the control group was(2.20±0.81)mmol·L-1 and HDL-C was(1.24±0.27)mmol·L-1.Compared with before treatment,the differences were statistically significant(P<0.01,P<0.05);The TC and TG of the observation group were(4.34±0.81)mmol·L-1 and(1.74±0.76)mmol·L-1,significantly lower than before treatment(P<0.01).(4)After treatment,the TG of the observation group was(1.74±0.76)mmol·L-1,signifi-cantly lower than that of the control group at the same period(2.20±0.81)mmol·L-1,and the difference was statistically significant(P<0.01).(5)The difference in FBG levels between the two groups after treatment and before treatment was statistically significant(P<0.05).(6)After treatment the difference of the degree of fatty liver of rank sum test results of the two groups of patients was sta-tistically significant(Z =-2.685,P<0.01).Conclusion:Qianggan Capsule can improve the glucose and lipid metabolism levels,pro-tect liver function,and reduce liver fat content in non-alcoholic fatty liver obese patients.
巴明玉;潘研;王娴;陈亚琳;燕树勋
河南中医药大学第一附属医院,河南 郑州 450000河南中医药大学第一附属医院,河南 郑州 450000||国家中医药管理局湖北陈氏瘿病学术流派传承工作室河南工作站,河南 郑州 450000
中医学
非酒精性脂肪肝强肝胶囊二甲双胍肥胖糖脂代谢肝功能
non-alcoholic fatty liverQianggan Capsulemetforminobesityglycolipid metabolismliver function
《中医学报》 2024 (002)
416-420 / 5
河南中医药管理局中医药科学研究专项课题项目(2019JDZX076);河南省卫生健康委中医药科学研究专项课题项目(20-21ZY2163);河南省中医药科学研究专项课题项目(2021JDZY084)
评论